La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática

Background: Abnormal small bowel motility, observed in liver cirrhosis, can be reversed with cisapride. Since both cisapride and liver disease are associated with prolonged QT interval, the possibility of adverse cardiovascular effects might be expected with cisapride treatment in these patients. Ai...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Quera P,Rodrigo, Madrid S,Ana María, Ugalde P,Héctor, Defilippi C,Carlos
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2000
Materias:	Cirrhosis QT interval Cisapride
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872000000800003
record_format	dspace
spelling	oai:scielo:S0034-988720000008000032005-11-29La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepáticaQuera P,RodrigoMadrid S,Ana MaríaUgalde P,HéctorDefilippi C,Carlos Cirrhosis QT interval Cisapride Background: Abnormal small bowel motility, observed in liver cirrhosis, can be reversed with cisapride. Since both cisapride and liver disease are associated with prolonged QT interval, the possibility of adverse cardiovascular effects might be expected with cisapride treatment in these patients. Aim: To evaluate QT interval and other electrocardiographic changes during long term treatment with cisapride in cirrhotic patients. Patients and methods: Forty seven cirrhotic patients were studied. Electrocardiogram was recorded and the QT interval corrected according to Bazzetts formula was determined (normal value <0.44 s). Seventeen patients were treated with cisapride, 10 mg tid for seven months and electrocardiographic controls were performed at the end of the treatment. Results: The mean corrected QT interval was 0.46 ± 0.03 s (range 0.4-0.53). 34 patients (64%) had QTc prolongation (0.47 ± 0,02 s). Statistically significant higher values of QTc were observed in patients at Child Pugh stage B and C compared to stage A. No statistically significant difference according to the etiology of liver disease, were observed. No changes in mean QTc duration were observed during cisapride treatment. Conclusions: In spite that a prolonged QTc was a frequent finding in our serie of selected patients, no cardiovascular adverse effects were observed with long term cisapride treatment. (Rev Méd Chile 2000; 128: 847-52).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.8 20002000-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800003es10.4067/S0034-98872000000800003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Cirrhosis QT interval Cisapride
spellingShingle	Cirrhosis QT interval Cisapride Quera P,Rodrigo Madrid S,Ana María Ugalde P,Héctor Defilippi C,Carlos La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
description	Background: Abnormal small bowel motility, observed in liver cirrhosis, can be reversed with cisapride. Since both cisapride and liver disease are associated with prolonged QT interval, the possibility of adverse cardiovascular effects might be expected with cisapride treatment in these patients. Aim: To evaluate QT interval and other electrocardiographic changes during long term treatment with cisapride in cirrhotic patients. Patients and methods: Forty seven cirrhotic patients were studied. Electrocardiogram was recorded and the QT interval corrected according to Bazzetts formula was determined (normal value <0.44 s). Seventeen patients were treated with cisapride, 10 mg tid for seven months and electrocardiographic controls were performed at the end of the treatment. Results: The mean corrected QT interval was 0.46 ± 0.03 s (range 0.4-0.53). 34 patients (64%) had QTc prolongation (0.47 ± 0,02 s). Statistically significant higher values of QTc were observed in patients at Child Pugh stage B and C compared to stage A. No statistically significant difference according to the etiology of liver disease, were observed. No changes in mean QTc duration were observed during cisapride treatment. Conclusions: In spite that a prolonged QTc was a frequent finding in our serie of selected patients, no cardiovascular adverse effects were observed with long term cisapride treatment. (Rev Méd Chile 2000; 128: 847-52).
author	Quera P,Rodrigo Madrid S,Ana María Ugalde P,Héctor Defilippi C,Carlos
author_facet	Quera P,Rodrigo Madrid S,Ana María Ugalde P,Héctor Defilippi C,Carlos
author_sort	Quera P,Rodrigo
title	La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
title_short	La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
title_full	La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
title_fullStr	La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
title_full_unstemmed	La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
title_sort	la cisaprida no altera el intervalo q-t prolongado en pacientes con cirrosis hepática
publisher	Sociedad Médica de Santiago
publishDate	2000
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800003
work_keys_str_mv	AT queraprodrigo lacisapridanoalteraelintervaloqtprolongadoenpacientesconcirrosishepatica AT madridsanamaria lacisapridanoalteraelintervaloqtprolongadoenpacientesconcirrosishepatica AT ugaldephector lacisapridanoalteraelintervaloqtprolongadoenpacientesconcirrosishepatica AT defilippiccarlos lacisapridanoalteraelintervaloqtprolongadoenpacientesconcirrosishepatica
_version_	1718435930761592832

La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática

Ejemplares similares